Ambalal Sarabhai Enterprises Ltd

Ambalal Sarabhai Enterprises has a debt-to-equity ratio of 0.36, indicating a relatively conservative capital structure. However, the company's liquidity position is rated as medium, with a current ratio of 0.98, suggesting limited short-term liquidity cushion. Free cash flow of INR 62.2 million is positive, but operating cash flow is negative at INR -176.2 million, signaling operational cash flow challenges. Profitability metrics show a return on equity of 3.52% and a return on assets of 1.83%, both below the typical thresholds for pharmaceutical firms, which often require higher returns to justify R&D and regulatory costs. The company's operating income is negative at INR -1.55 million, indicating operational inefficiencies or cost overruns. The company's revenue is concentrated in two segments: Pharmaceuticals and Electronics. The pharmaceutical segment includes both domestic and international operations, with Asence Inc. handling international markets and Suvik Hitek Pvt. Ltd. managing domestic generics and veterinary products. No geographic breakdown is provided, but the company's exposure to India's domestic market is likely significant. Outlook data is not provided, but historical revenue of INR 1.96 billion suggests a stable but not growing business. The company's operating losses and negative operating cash flow raise concerns about its ability to sustain growth without external financing. Risk factors include medium liquidity risk and a negative net cash position after subtracting total debt. Dilution risk is rated as low, with no near-term pressure expected. The company's capital expenditure of INR -27.2 million suggests a reduction in investment, which may impact long-term growth. Recent filings and transcripts are not provided in the input data, so no specific events can be cited. However, the company's financial snapshot indicates a need for operational improvements to address cash flow and profitability issues.